Authors
Tasson da Costa Rodrigues, Naga Suresh Kola, Dhruv Patel, Alaa Ibrahim, Shamsuddeen Yusuf Ma'aruf, Azita Haddadi, Mark Fenton, Gabriel Kristian Pedersen, Jeffrey M Chen, Neeraj Dhar, Aneesh Thakur
Published in
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. Pages 115289. Nov 09, 2026. Epub Nov 09, 2026.
Abstract
Subunit vaccines are typically given through injections, which limits mucosal immunity. Most adjuvants do not stimulate mucosal responses but using lipid nanoparticles (LNPs) encapsulating polyinosinic-polycytidylic acid (poly(I:C)), a toll-like receptor 3 agonist, could enhance the immune response in the lungs. We tested LNPs made from four ionizable lipids using a microfluidic mixing method to encapsulate poly(I:C) at different concentrations. The LNPs were evaluated for particle size, polydispersity index (PDI), poly(I:C) encapsulation efficiency (EE %), morphology, and NF-κB activation over a 4-week period. Mice were immunized with LNPs containing poly(I:C) and a protein antigen from Mycobacterium tuberculosis via the intrapulmonary route. Results showed that LNPs formulated with low molecular weight poly(I:C) exhibited the most favorable physicochemical properties and higher NF-κB induction compared to those made with high molecular weight poly(I:C), although a statistically significant difference was only observed for PDI. LNPs made with the ionizable lipid SM-102 were the most stable. Immunized mice had enhanced levels of serum and mucosal antibodies. Notably, the most prominent effect of the poly(I:C)-LNPs was the generation of significant cytokine-producing cells in the lungs and spleen, alongside memory cells in the lungs, spleen, and lymph nodes. In conclusion, pulmonary immunization with poly(I:C)-LNPs induced both systemic and mucosal immunity, though further investigation into antigen-specific protection is necessary. Overall, this work demonstrates new possibilities for vaccine development against respiratory infections.
PMID:
43003275
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0